Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | ADH7 | P40394 | 1/20 | 0.34 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441910 | 1.00 | ADH1B (0.34) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL6801537 | 0.97 | — | — | |
| SCHEMBL2240670 | 0.97 | — | — | |
| SCHEMBL8941237 | 0.92 | — | — | |
| SCHEMBL962973 | 0.92 | — | — | |
| SCHEMBL1482074 | 0.86 | — | — | |
| SCHEMBL1482073 | 0.86 | — | — | |
| SCHEMBL29860701 | 0.80 | ADH1B (0.36) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL28216071 | 0.78 | ADH1B (0.37) | ADH1BADH1CADH1AADH4ADH7 | |
| SCHEMBL11144495 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0205834-B1 | 7-THIABICYCLOHEPTANE SUBSTITUTED ETHERS | E.R. Squibb & Sons, Inc. (US) | 1990-10-31 | — | — | EP | claimed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | claimed |
| CN-107027309-B | Antibacterial agent | 昆士兰大学 | 2021-10-01 | — | — | CN | disclosed |
| US-10947271-B2 | Antibacterial agents | THE UNIVERSITY OF QUEENSLAND (AU) | 2021-03-16 | — | — | US | disclosed |
| US-20170204138-A1 | ANTIBACTERIAL AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2017-07-20 | — | — | US | disclosed |
| EP-3105244-A1 | ANTIBACTERIAL AGENTS | The University Of Queensland (AU) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015117196-A1 | ANTIBACTERIAL AGENTS | THE UNIVERSITY OF QUEENSLAND (AU) | 2015-08-13 | — | — | WO | disclosed |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | J. Uriach Y Compañia S.A. (ES) | 2005-06-30 | — | — | US | disclosed |
| EP-1495044-A1 | HETEROCYCLIC AMIDES WITH ALPHA-4 INTEGRIN ANTAGONIST ACTIVITY | J. Uriach y Compania S.A. (ES) | 2005-01-12 | — | — | EP | disclosed |
| US-20040133938-A1 | Use of lipoic acid in plant culture media | MONSANTO TECHNOLOGY LLC | 2004-07-08 | — | — | US | disclosed |
| US-20040023882-A1 | PTH derivatives resistant to skin proteases | THERATECHNOLOGIES INC. (CA) | 2004-02-05 | — | — | US | disclosed |
| EP-1061914-A1 | LIPOIC ACID ANALOGS | REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-12-27 | — | — | EP | disclosed |
| CN-1267281-A | Glucagon antagonists/inverse agonists | NOVO NORDISK AS (DK) | 2000-09-20 | — | — | CN | disclosed |
| EP-0994848-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 2000-04-26 | — | — | EP | disclosed |
| WO-1999045922-A1 | LIPOIC ACID ANALOGS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1999-09-16 | — | — | WO | disclosed |
| WO-1999001423-A1 | GLUCAGON ANTAGONISTS/INVERSE AGONISTS | NOVO NORDISK A/S (DK) | 1999-01-14 | — | — | WO | disclosed |
| EP-0205834-B1 | 7-THIABICYCLOHEPTANE SUBSTITUTED ETHERS | E.R. Squibb & Sons, Inc. (US) | 1990-10-31 | — | — | EP | disclosed |
| US-4333940-A | Ring-fluorinated 4-(monosubstituted-amino) phenyl compounds in inhibiting atherosclerotic lesion development | AMERICAN CYANAMID COMPANY (US) | 1982-06-08 | — | — | US | disclosed |
| US-4243609-A | ANTILIPEMIC AGENTS, ANTIATHEROSCLEROTIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1981-01-06 | — | — | US | disclosed |
| EP-0003663-A2 | Amino-substituted phenyl and heteroaryl compounds, process for their preparation and pharmaceutical compositions containing them | AMERICAN CYANAMID COMPANY (US) | 1979-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040133938-A1 | Use of lipoic acid in plant culture media | TTPA, TST, LRAT | ADH1B 530/4885ADH1C 2632/4885ADH1A 1800/4885 |
| US-20170204138-A1 | ANTIBACTERIAL AGENTS | VNN1, ASNS, AAAS | ADH1B 4034/4885ADH1C 4847/4885ADH1A 4650/4885 |
| US-10947271-B2 | Antibacterial agents | VNN1, ASNS, AAAS | ADH1B 4034/4885ADH1C 4847/4885ADH1A 4650/4885 |
| US-20050143391-A1 | Heterocyclic amides with alpha-4 integrin antagonist activity | ITGB4, ITGA4, ITGA1 | ADH1B 1794/4885ADH1C 1895/4885ADH1A 829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.